Constellation Pharmaceuticals
OverviewSuggest Edit
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel drugs that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Its integrated epigenetics platform helps to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity.
| Type | Public | |
| Founded | 2008 | |
| HQ | Cambridge, MA, US | Map |
| Website | constellationpharma.com | |
| Employee Ratings | More |
Recent NewsAll News
- Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST
- Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
- SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Constellation Pharmaceuticals, Inc. Buyout
Key People/Management at Constellation Pharmaceuticals
Jigar Raythatha
President, Chief Executive Officer
Barbara Krebs-Pohl
Chief Integration Officer
Mark A. Goldsmith
Executive Chairman
Jeffrey Humphrey
Chief Medical Officer
Patrick Trojer
Chief Scientific Officer
Mohan Bala
Chief Operating Officer
Constellation Pharmaceuticals Office Locations
Constellation Pharmaceuticals has offices in Cambridge and Boston
Cambridge, MA, US (HQ)
215 First St
Boston, MA, US
470 Atlantic Ave 14th Floor
Constellation Pharmaceuticals Financials and Metrics
Constellation Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (Q1, 2018) | (12.1m) |
EBIT (Q1, 2018) | (12.2m) |
Market capitalization (21-Jul-2021) | 1.6b |
Closing stock price (21-Jul-2021) | 34.0 |
Cash (31-Mar-2018) | 71.5m |
EV | 1.6b |
Constellation Pharmaceuticals's current market capitalization is $1.6 b.
Annual
| USD | FY, 2016 | FY, 2017 |
|---|---|---|
Cash | 36.9m | 16.4m |
Prepaid Expenses | 515.0k | 1.3m |
Current Assets | 37.4m | 17.7m |
PP&E | 1.0m | 1.1m |
Quarterly
| USD | Q1, 2018 |
|---|---|
Cash | 71.5m |
Prepaid Expenses | 1.9m |
Current Assets | 73.4m |
PP&E | 1.0m |
Annual
| USD | FY, 2016 | FY, 2017 |
|---|---|---|
Net Income | (34.5m) | (35.4m) |
Depreciation and Amortization | 203.0k | 474.0k |
Accounts Payable | 423.0k | 67.0k |
Cash From Operating Activities | (32.8m) | (37.6m) |
Quarterly
| USD | Q1, 2017 | Q1, 2018 |
|---|---|---|
Net Income | (5.7m) | (12.1m) |
Depreciation and Amortization | 98.0k | 135.0k |
Accounts Payable | (1.3m) | 562.0k |
Cash From Operating Activities | (11.4m) | (11.8m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | -0.3 x |
Constellation Pharmaceuticals Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Constellation Securities Corporation |
Constellation Pharmaceuticals Cybersecurity Score
Constellation Pharmaceuticals Environment, Social & Governance (ESG) Ratings
Constellation Pharmaceuticals Online and Social Media Presence
1.33k Twitter followers
Constellation Pharmaceuticals has 1.33k Twitter Followers. The number of followers has increased 0.1% month over month and increased 1.7% quarter over quarter
Constellation Pharmaceuticals's Trends
Constellation Pharmaceuticals News and Updates
June 11, 2021
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical tri…
June 05, 2021
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST
NEW YORK, June 4, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
June 04, 2021
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongo…
June 02, 2021
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Constellation Pharmaceuticals, Inc. Buyout
WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Constellation Pharmaceuticals, Inc. (“Constellation”) (NASDAQ GS: CNST) regarding possible breaches of fiduciary duties and other violations of law related to Constellation’s agreement to be …
June 02, 2021
Thinking about buying stock in Constellation Pharmaceuticals, Neovasc, Orbital Energy, Washington Prime Group, or Urban One?
NEW YORK, June 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNST, NVCN, OEG, WPG, and UONE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 31, 2021
Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual …
Constellation Pharmaceuticals Blogs
April 29, 2022
The JMP Securities Life Sciences Conference (New York City)
The JMP Securities Life Sciences Conference (New York City)
Altinger-RalleI
Fri, 04/29/2022 - 12:17
In Person
Thu, 06/16/2022 - 12:16
Thu, 06/16/2022 - 12:16
April 29, 2022
J.P. Morgan European Healthcare Conference (London)
J.P. Morgan European Healthcare Conference (London)
Altinger-RalleI
Fri, 04/29/2022 - 12:15
In Person
Thu, 06/23/2022 - 12:10
Thu, 06/23/2022 - 12:10
February 04, 2022
14th Kempen Life Sciences Conference (Amsterdam)
14th Kempen Life Sciences Conference (Amsterdam)
danilo.brandt
Fri, 02/04/2022 - 17:18
Virtual
Thu, 04/21/2022 - 09:00
Thu, 04/21/2022 - 18:00
February 04, 2022
SVB Leerink 11th Annual Global Healthcare Conference
SVB Leerink 11th Annual Global Healthcare Conference
danilo.brandt
Fri, 02/04/2022 - 17:14
Virtual
Thu, 02/17/2022 - 09:00
Thu, 02/17/2022 - 18:00
January 17, 2022
Third Quarter Interim Statement 2022
Third Quarter Interim Statement 2022
GruentgensM
Mon, 01/17/2022 - 13:50
Virtual
Wed, 11/16/2022 - 12:00
Wed, 11/16/2022 - 23:59
January 17, 2022
Half-Year Report 2022
Half-Year Report 2022
GruentgensM
Mon, 01/17/2022 - 13:50
Virtual
Wed, 08/03/2022 - 12:00
Wed, 08/03/2022 - 23:59
Constellation Pharmaceuticals Frequently Asked Questions
When was Constellation Pharmaceuticals founded?
Constellation Pharmaceuticals was founded in 2008.
Who are Constellation Pharmaceuticals key executives?
Constellation Pharmaceuticals's key executives are Jigar Raythatha, Barbara Krebs-Pohl and Mark A. Goldsmith.
How many employees does Constellation Pharmaceuticals have?
Constellation Pharmaceuticals has 82 employees.
Who are Constellation Pharmaceuticals competitors?
Competitors of Constellation Pharmaceuticals include Imago BioSciences, Omega Therapeutics and Moderna.
Where is Constellation Pharmaceuticals headquarters?
Constellation Pharmaceuticals headquarters is located at 215 First St, Cambridge.
Where are Constellation Pharmaceuticals offices?
Constellation Pharmaceuticals has offices in Cambridge and Boston.
How many offices does Constellation Pharmaceuticals have?
Constellation Pharmaceuticals has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies